Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone Co-administration in Patients With Type II Diabetes With Insufficient Glycemic Control With Metformin and Empagliflozin Combination Therapy

NCT06571591 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT06571591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06571591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone Co-administration in Patients With Type II Diabetes With Insufficient Glycemic Control With Metformin and Empagliflozin Combination Therapy
Lead sponsor
Celltrion
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2024
Completion date
May 4, 2026
Enrollment
606 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm